eligibility_summary
Eligible: FL grade 1–3a or MZL, relapsed/refractory after ≥1 prior systemic therapy incl anti‑CD20, measurable disease (CT/MRI), ECOG 0–2, adequate hematologic/organ function, agree to lenalidomide precautions (teratogenic risk counseling, no blood donation, no sharing). Exclude: CNS lymphoma/involvement, transformed DLBCL/other histology, relevant CNS disease, other cancers unless cured ≥3 yrs (except certain in situ/localized prostate), significant active disease/condition, drug allergy, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 trial in relapsed/refractory follicular and marginal zone lymphoma compares odronextamab+lenalidomide vs rituximab+lenalidomide (R2). Odronextamab: intravenous anti‑CD20×anti‑CD3 bispecific antibody (T‑cell–redirecting IgG) that links CD3 on T cells to CD20 on B cells, activating cytotoxic T cells and inducing lysis of CD20+ malignant B cells. Rituximab: anti‑CD20 chimeric monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis. Lenalidomide: oral immunomodulatory drug (IMiD, cereblon E3 ligase modulator) that degrades IKZF1/3, enhances T‑ and NK‑cell activity, reduces Tregs, and has anti‑angiogenic/direct tumor effects. Targets/pathways: CD20 on malignant B cells, CD3 on T cells, cereblon–IKZF1/3 axis, immune effector mechanisms (T‑cell activation/cytokines, NK‑cell ADCC, complement).